Delay in diagnosis of patients with head-and-neck cancer in Canada: impact of patient and provider delay. by Kassirian, S et al.
Western University 
Scholarship@Western 
Paediatrics Publications Paediatrics Department 
10-1-2020 
Delay in diagnosis of patients with head-and-neck cancer in 






See next page for additional authors 
Follow this and additional works at: https://ir.lib.uwo.ca/paedpub 
 Part of the Pediatrics Commons 
Citation of this paper: 
Kassirian, S; Dzioba, A; Hamel, S; Patel, K; Sahovaler, A; Palma, D A; Read, N; Venkatesan, V; Nichols, A C; 
Yoo, J; Fung, K; Mendez, A; and MacNeil, S D, "Delay in diagnosis of patients with head-and-neck cancer in 
Canada: impact of patient and provider delay." (2020). Paediatrics Publications. 525. 
https://ir.lib.uwo.ca/paedpub/525 
Authors 
S Kassirian, A Dzioba, S Hamel, K Patel, A Sahovaler, D A Palma, N Read, V Venkatesan, A C Nichols, J 
Yoo, K Fung, A Mendez, and S D MacNeil 
This article is available at Scholarship@Western: https://ir.lib.uwo.ca/paedpub/525 
e467Current Oncology, Vol. 27, No. 5, October 2020 © 2020 Multimed Inc.
ORIGINAL ARTICLE
Correspondence to: Danielle Macneil, Department of Otolaryngology Head and Neck Surgery, 800 Commissioners Road E, London, Ontario  N6A 5W9. 
E-mail: Danielle.macneil@lhsc.on.ca  n  DOI: https://doi.org/10.3747/co.27.6547
Delay in diagnosis of patients with 
head-and-neck cancer in Canada:  
impact of patient and provider delay
S. Kassirian md,* A. Dzioba phd,† S. Hamel md,† K. Patel md,‡ A. Sahovaler md,†  
D.A. Palma md msc phd,§ N. Read md,§ V. Venkatesan dlo,§ A.C. Nichols md,†  
J. Yoo md,† K. Fung md,† A. Mendez md,† and S.D. MacNeil md msc†
INTRODUCTION
In 2019, head-and-neck cancers (hncs) had a projected 
incidence of approximately 6500 new cases in Canada, 
with approximately 1800 related deaths1. The modality of 
treatment is site- and stage-dependent, but hnc is managed 
largely with surgery or radiation, or both2. Tumour stage 
at presentation is one of the most significant prognostic 
factors for hnc outcome3. Delays in treatment initiation 
have been well-documented to result in advanced clinical 
presentation4–8. However, the impact of delay in diagno-
sis on survival and quality-of-life outcomes is less well 
known9,10. Presumably, patients who experience a delay in 
diagnosis present with more advanced-stage cancer and 
experience poor outcomes; however, such a link has not 
been established.
In Ontario, a substantial effort has been made to re-
duce wait times for patients with hnc once a referral is made 
to a head-and-neck oncologist. Referrals are received from 
a variety of sources, including general otolaryngologists, 
dentists, oral surgeons, and general practitioners. Wait 
times to consultation and then from initial consultation to 
treatment are tracked, and efforts are ongoing at all major 
head-and-neck institutions to reduce wait times. As of 
January 2020 in Ontario, 89% of patients are seen for a first 
hnc surgical appointment within the target time, and 70% 
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of patients are treated within the target time from decision 
to cancer surgery11. Similar data have been reported for hnc 
radiation wait times12. Although the quality improvement 
process has been a success, studies suggest that a much 
more significant delay occurs before the initial consulta-
tion with a head-and-neck oncologist, with many patients 
reporting multiple referrals, misdiagnoses, prolonged wait 
times for biopsies and imaging, and lack of awareness on 
the part of both the provider and the patient about the signs 
and symptoms of hnc13,14.
The delay before assessment by a head-and-neck 
oncologist can be divided into two main phases: patient 
delay and provider delay. Patient delay results when indi-
viduals do not immediately seek medical attention for a new 
symptom and is defined as the time from first symptom to 
first visit with a health care provider (hcp). Provider delay 
occurs once the patient has made initial contact with the 
first hcp for a symptom and is defined here as the time from 
the visit with the hcp by the patient to the time of pres-
entation at the multidisciplinary team (mdt) clinic. The 
total length of patient and provider delay has been poorly 
studied to date, and the causes for the component delays 
are largely unknown.
In the present study, we sought to determine, for a 
prospective cohort of consecutive new patients with hnc, 
the lengths and causes of delay until presentation to the 
head-and-neck oncologist (mdt clinic) at our high-volume 
hnc centre. We hypothesized that a significant proportion 
of the delay in presentation to the head-and-neck mdt clinic 
would result from provider delay and multiple hcp referrals.
METHODS
Inclusion Criteria
All new adult patients with hnc presenting to the head-
and-neck cancer mdt clinic at the London Regional Cancer 
Program from September 2017 to September 2018 were eli-
gible for inclusion. The London Regional Cancer Program, 
which services Southwestern Ontario, sees approximately 
400 new patients with hnc per year. All patients presenting 
to the head-and-neck mdt clinic must have a biopsy-proven 
diagnosis of cancer. With few exceptions, once a refer-
ral is made to the head-and-neck mdt, patients are seen 
within 2 weeks in the clinic, with most being seen in less 
than 1 week. Patients are assessed by a head-and-neck sur-
gical oncologist, a head-and-neck radiation oncologist, and 
other members of the mdt. We recruited all new adult pa-
tients who were able to read and write in English, excluding 
patients with recurrent cancer and patients with non-hncs.
Survey Development
A survey was developed based on a previously validated 
Cancer Symptom Interval Measure questionnaire targeted 
for patients with malignancy (Table i)15. The questionnaire 
queried patients about presenting symptoms, the timing 
of initial symptoms or signs, the time of first visit with a 
hcp, and the number of health care visits before referral 
to the head-and-neck mdt clinic. Patient demograph-
ics—including age, sex, history of smoking, alcohol use, 
education, employment, and place of residence—were 
also requested. The survey was distributed in hard copy. 
The Research Ethics Board at Western University approved 
the study (no. 109197). All patients who participated in the 
study signed a written consent form.
Data Collection
All new consecutive patients with hnc who presented to 
the head-and-neck mdt were invited to participate in the 
study. Patients were approached at the time of their initial 
consultation at the clinic. A diagnosis of cancer had been 
delivered, but in some cases, patients were not aware of the 
treatment that they would receive. The study coordinator 
obtained consent and administered the study question-
naire. Although the survey was self-administered, given 
the distress that patients were experiencing and the dif-
ficulty that some patients had in remembering timelines, 
the study coordinator was present with the patients while 
they completed the questionnaire to assist with question 
comprehension and to encourage patients to do their best 
with memory recollection. Additional information about 
the exact cancer type, site, and staging was collected from 
patient charts. The TNM tumour staging followed the 
7th edition of the American Joint Committee on Cancer 
staging manual16.
Study Outcomes
The two primary study outcomes were these points of pos-
sible delay: time from the patient first noticing symptoms 
to first presentation to a hcp (patient-related delay) and 
time from first presentation to a hcp to first presentation 
to the mdt clinic (provider-related delay). Those intervals 
were further segmented into time between making an 
appointment with a hcp and being seen, seeing a hcp to 
imaging, and seeing a hcp to biopsy. We also recorded the 
number of hcps that a patient saw before being referred to 
the mdt clinic.
Subgroup analyses were performed to determine 
whether there were associations of clinical and patient 
characteristics (stage of disease, hnc site, history of smok-
ing, history of alcohol use, living situation, age, sex, and 
education) with the study outcomes already described.
Data Analysis
Study outcomes were descriptively analyzed. Frequency 
statistics and means with standard deviations were cal-
culated for patient demographics, clinical presentation, 
and time intervals in the diagnostic pathway (that is, from 
onset of symptoms, to time taken to make an appointment, 
to diagnosis). A Pearson chi-square or Fisher exact test 
(where appropriate) was conducted to compare differences 
in rates of presenting symptoms, demographic and clinical 
features, and patient-perceived delays in care and seeking 
medical attention. The independent samples t-test or an-
alysis of variance (where appropriate) was conducted to 
compare mean differences for each subgroup on contin-
uous study outcomes, including demographics, number 
of hcps seen, and intervals in the care pathway. Data were 
analyzed using the IBM SPSS Statistics software application 
(version 25.0: IBM, Armonk, NY, U.S.A.). Statistical signif-
icance was determined a priori at the alpha level of 0.05.
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TABLE I London Health Sciences Centre multidisciplinary team patient survey for referral timings
Date _____/_____/_____     Study ID number ______________
Section 1
1) What is the reason for today’s appointment?
_____________________________________________________________________________________________________________________
Section 2
1) Please check ALL symptoms, those that were present when you first became aware of this health problem:
o Mouth sore o Trouble opening mouth o Stuffy nose
o Lump in the neck o Trouble chewing o Decreased sense of smell
o White patch o Trouble swallowing o Trouble hearing
o Red patch o Pain with swallowing o Draining ear
o Pain o Change in voice o Double vision
o Bleeding o Trouble breathing o Watery eyes
o Loose teeth o Headaches o Numbness or tingling
o Dentures that no longer fit o Runny nose o New skin growth
o Other ______________
A. Do you have a family doctor?   o Yes o No
B. When did your symptoms first occur?   _____/_____/_____ (Estimate the date)
C. When did you first tell a health care provider?   _____/_____/_____ (Estimate the date)
D. Who did you first discuss your symptoms with?
o Family doctor o Dentist o Emergency
o Walk-in clinic o Oral surgeon o Nurse
o Other ______________
E. How long did it take you to see that health care provider?   _____/_____/_____ (Estimate the date)
F. Did this health care provider examine the area of concern?   o Yes o No
2) Do you think there was a delay in your care?   o Yes o No
3) Did you wait in seeking medical attention for your symptoms?   o Yes o No
Section 3
This section will provide us with the referral process and patient pathway in diagnosis of their head and neck cancer.
Please list the specialties and the dates seen for all health care providers you have seen for the problem listed above. Health care providers 
include ENT, oral surgeons, dentists, family doctors, emergency physicians, naturopaths, nurses, chiropractors, etc.
Health Care Provider 1
Specialty ______________   Month/year 1st seen _______/_______   Number of times seen _______
Health Care Provider 2
Specialty ______________   Month/year 1st seen _______/_______   Number of times seen _______
Health Care Provider 3
Specialty ______________   Month/year 1st seen _______/_______   Number of times seen _______
Health Care Provider 4
Specialty ______________   Month/year 1st seen _______/_______   Number of times seen _______
Health Care Provider 5
Specialty ______________   Month/year 1st seen _______/_______   Number of times seen _______
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TABLE I Continued
Section 4
This section will ask you some questions about smoking, alcohol intake, your employment status.
1) Are you/have you ever been a smoker?   o Yes o No
A. How much do you smoke per day? Please specify packs or cigarettes.   _______/day
B. How many years have you smoked for?   _______ years
C. If you quit, how many years ago did you quit?   _______ years
2) How many alcoholic drinks do you have per day? Please specify what the drink is: ________ ____________________
3) Which best describes your employment status? (Please tick one box only)
o Employed full-time o Unemployed (not seeking work) o Permanent sick/disabled
o Employed part-time o Retired o Temporarily sick/disabled
o Unemployed (seeking work) o Student o Looking after family/home
o Other ______________
4) What is your highest education level? (Please tick one box only)
o Degree (or equivalent) o High school
o Diploma (or equivalent) o Did not complete high school
Section 5
This questionnaire helps your physician to know how you are feeling. Read every sentence, place an “X” on the answer that best describes 
how you have been feeling during the LAST WEEK. You do not have to think too much to answer. In this questionnaire, spontaneous 
answers are more important.
A I feel tense or ‘wound up’ D I feel as if I am slowed down
Most of the time 3 Nearly all the time 3
A lot of the time 2 Very often 2
From time to time (occasionally) 1 Sometimes 1
Not at all 0 Not at all 0
D I still enjoy the things I used to enjoy A I get a sort of frightened feeling like “butterflies” in the stomach
Definitely as much 0 Not at all 0
Not quite as much 1 Occasionally 1
Only a little 2 Quite often 2
Hardly at all 3 Very often 3
A I get a sort of frightened feeling as if something awful is 
about to happen
D I have lost interest in my appearance
Very definitely and quite badly 3
Definitely 3
Yes, but not too badly 2
I don’t take as much care as I should 2
A little, but it doesn’t worry me 1
I may not take quite as much care 1
Not at all 0
I take just as much care 0
D I can laugh and see the funny side of things A I feel restless as I have to be on the move
As much as I always could 0 Very much indeed 3
Not quite so much now 1 Quite a lot 2
Definitely not so much now 2 Not very much 1
Not at all 3 Not at all 0
A Worrying thoughts go through my mind D I look forward with enjoyment to things
A great deal of the time 3 As much as I ever did 0
A lot of the time 2 Rather less than I used to 1
From time to time, but not often 1 Definitely less than I used to 2
Only occasionally 0 Hardly at all 3
D I feel cheerful A I get sudden feelings of panic
Not at all 3 Very often indeed 3
Not often 2 Quite often 2
Sometimes 1 Not very often 1
Most of the time 0 Not at all 0
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TABLE I Continued
A I can sit at ease and feel relaxed D I can enjoy a good book or radio/TV program
Definitely 0 Often 0
Usually 1 Sometimes 1
Not often 2 Not often 2
Not at all 3 Very seldom 3
Section 6 (health care provider use only)
Type and location of patient’s cancer
_____________________________________________________________________________________________________________________
TNM staging of patient’s cancer   T_______ N_______ M_______   Date of staging _____/_____/_____
Some people experience pain or discomfort for different reasons
Do you have any pain or discomfort? If yes, please explain _________________________________
Do you think your pain is controlled?
 If yes, please answer the following
 What does it feel like? _________________________________
 What makes your pain worse? _________________________________
 What makes your pain better? _________________________________
Please check if you live o alone   o with spouse   o with family   o other ______________
Do you have any children? o Yes o No   If yes, do they live at home? ______________
What is your occupation? _______________________________________________________________





o Family doctor o Dentist o Oral surgeon o Emergency o Nurse o Other ______________
Investigations:
o Ultrasound o CT scan o MRI o Biopsy
1st Health Care Visit
Date (estimate) _____/_____/_____
Specialty:
o Family doctor o Dentist o Oral surgeon o Emergency o Nurse o Other ______________
Investigations:
o Ultrasound o CT scan o MRI o Biopsy
2nd Health care visit
Date (estimate) _____/_____/_____
Specialty:
o Family doctor o Dentist o Oral surgeon o Emergency o Nurse o Other ______________
Investigations:
o Ultrasound o CT scan o MRI o Biopsy
3rd Health Care Visit
Date (estimate) _____/_____/_____
Specialty:
o Family doctor o Dentist o Oral surgeon o Emergency o Nurse o Other ______________
Investigations:
o Ultrasound o CT scan o MRI o Biopsy
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RESULTS
Baseline Characteristics
Tables ii and iii summarize patient demographics and 
characteristics of the malignancy. Mean age of the patients 
was 67.5 years, and most patients were men (78.4%). The 
most common site was the oral cavity, with squamous cell 
carcinoma constituting 78.4% of the histology. There was 
an even distribution of patients presenting with early- and 
advanced-stage disease. In terms of smoking history, 64 pa-
tients (62.7%) had a history of smoking. The only baseline 
characteristic that was significantly different between the 
early-stage and advanced-stage groups was number of years 
smoked: compared with individuals in the advanced-stage 
group, individuals in the early-stage group had smoked for 
a fewer number of years (mean: 25.6 years vs. 34.2 years; 
p = 0.04). No baseline characteristics differed significantly 
between the early-stage and advanced-stage groups.
Initial Presenting Symptoms
The most common presenting symptom in all patients was 
a lump in the neck (38.2%); other symptoms were pain in 
the primary malignancy site (24.5%), a mouth sore (20.6%), 
change in voice (16.7%), and a new skin growth (14.7%). 
Compared with the early-stage group, the advanced-stage 
group had a higher rate of having a lump in the neck as their 
presenting symptom (43.1% vs. 27.9%, p = 0.05). Otherwise, 
TABLE I Continued
Section 6 (health care provider use only)
4th Health Care Visit
Date (estimate) _____/_____/_____
Specialty:
o Family doctor o Dentist o Oral surgeon o Emergency o Nurse o Other ______________
Investigations:
o Ultrasound o CT scan o MRI o Biopsy
5th Health Care Visit
Date (estimate) _____/_____/_____
Specialty:
o Family doctor o Dentist o Oral surgeon o Emergency o Nurse o Other ______________
Investigations:















ENT = ear, nose, throat; CT = computed tomography; MRI = magnetic resonance imaging.
there were no significant differences in initial symptoms 
between the early- and advanced-stage groups.
Intervals in the Care Pathway
Table iv summarizes the intervals between events in the 
diagnostic pathway from symptom onset to first visit to 
the mdt clinic. Mean time from symptom onset to pres-
entation to a hcp was 3.9 months—effectively, the patient- 
delay interval. It took an average of 0.2 months (7.1 days) to 
obtain an appointment with a hcp once contact had been 
made by the patient. The time from presentation to first 
hcp to the mdt appointment was 10.7 months—effectively, 
the provider-delay interval. The mean time from first hcp 
visit to biopsy was 9.8 months. The total time from first 
onset of symptoms to presentation at the mdt clinic was 
15.1 months. No correlation of any of those time intervals 
with age, sex, education status, living situation, having 
children, having a family doctor, history of smoking, history 
of alcohol use, tumour site, or presentation with early- or 
advanced-stage disease was observed (p > 0.05, Table iv).
HCPs Seen Before the MDT Clinic Appointment
The mean number of hcps seen before the appointment 
at the mdt clinic was 3 (range: 1–7). More than 3 hcps had 
been seen by 51% of patients with early-stage disease and 
by 59.5% of patients with advanced-stage disease. No sig-
nificant differences were noted in the mean number of hcps 
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TABLE II Patient demographics
Characteristic Disease stage p 
ValueaEarly Advanced Overall
Patients (n) 43 51 102b
Mean age (years) 68.65±12.04 68.27±11.13 67.51±11.98 0.88
Sex [n (%) men] 33 (76.7) 41 (80.4) 80 (78.4) 0.67
Employment [n (%) retired] 26 (60.5) 33 (64.7) 62 (60.8) 0.67
Education [n (%) ≥high school] 34 (79.1) 36 (70.6) 77 (75.3) 0.35
Living situation [n (%) alone] 11 (25.5) 10 (19.6) 22 (21.6) 0.49
Have children [n (%)] 31 (72.1) 40 (78.4) 76 (74.5) 0.48
Have a family doctor [n (%)] 43 (100) 46 (90.2) 96 (94.1) 0.11
Smoking status
History of smoking [n (%)] 26 (60.5) 33 (64.7) 64 (62.7) 0.53
Currently smoking [n (%)] 7 (16.3) 13 (25.5) 23 (22.5) 0.55
Mean years smoked 25.60±16.43 34.19±12.22 29.97±14.43 0.04
Mean cigarettes daily 19.90±14.12 18.23±11.70 18.41±12.53 0.63
Mean pack–years 30.35±30.90 31.41±21.17 29.73±25.23 0.88
Alcohol status
Current user [n (%)] 29 (67.4) 37 (72.5) 71 (69.6) 0.72
Previous abuse [n (%)] 2 (4.7) 2 (3.9) 4 (3.9) 0.86
Mean drinks daily 1.92±1.60 2.38±2.08 2.10±1.85 0.42
a Significant values appear in boldface type. 
b Of 102 total patients, 8 had disease of unknown stage based on American Joint Committee on Cancer criteria.
 
seen before the mdt clinic visit, including by cancer stage 
group (p > 0.05).
Patient Perception of Delay
Of the surveyed patients, 29% discussed their symptoms 
at a routine visit with their primary hcp. A statistically sig-
nificantly higher proportion of patients in the early-stage 
group (41.9%) than in the advanced-stage group (15.7%) 
spoke to their primary hcp about their symptoms during a 
routine visit (p = 0.01). After their symptoms started, 51% 
of patients delayed seeking medical care. A statistically 
significant higher proportion of patients in the early-stage 
group (67.4%) than in the advanced-stage group (41.2%) 
waited to seek medical attention for their symptoms 
(p = 0.01). A perception of a delay in their care was ex-
pressed by 55% of patients, with no difference between 
the early- and advanced-stage groups (p > 0.05), and 52% 
of patients expressed regret and wished that they had done 
things differently to speed up their care, with no difference 
between the early- and advanced-stage groups (p > 0.05).
No differences in perceived delay were associated with 
education level, employment status, children, smoking or 
alcohol use, or early- and advanced-stage disease (p > 0.05). 
However, a significant difference with respect to waiting 
to seek medical attention was noted between patients 
who lived alone and those who did not (68.2% vs. 42.9% 
respectively, p = 0.04).
DISCUSSION
In this study, we report that the total delay in diagnosis from 
first symptom onset to presentation at our head-and-neck 
mdt clinic was 15.07 months. The greatest delay was 
provider- caused delay (from first hcp encounter to presen-
tation at the mdt clinic). On average, 50% of patients had to 
see 3 hcps before presenting to the mdt clinic. We addressed 
total delay in diagnosis for all hnc sites and considered a 
wide variety of relevant patient- and tumour-related fac-
tors, finding no correlation of any patient or tumour factor 
with delay in presentation.
The mean patient-caused delay in our study from 
first symptom onset to presentation to a hcp was almost 
4 months. Previous studies have demonstrated a similar 
mean patient delay: 3.7–4.3 months for all hncs13,17 and 
3.5–5.4 months for oral cancers18. Several studies found that 
certain patient factors were associated with the interval 
before first presentation to a hcp: fear, lack of pain, lack of 
suspicion of cancer, smoking history, and socioeconomic 
factors17,19,20. We did not find that tumour site, socioeco-
nomic factors, or smoking history correlated with patient 
delay. In the literature, findings are variable, with some 
studies demonstrating a correlation between cancer site 
and patient delay17,21,22 and other studies, not20,22–24.
We did not find that stage at presentation was associ-
ated with patient delay. The association between patient 
delay and stage at presentation has previously been studied 
with varying results7,20,22,23. Given that our study included 
patients with hnc at all sites, the presenting symptoms 
and intensity of symptoms could have been quite variable, 
which might account for the lack of an association. Given 
that 19.6% of patients in our study had an oropharynx 
cancer, which, when related to infection with the human 
papillomavirus, often presents with an asymptomatic 
neck mass25, the lack of correlation for site and stage of 
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presentation with patient delay might have been influenced 
by that subgroup. A larger sample size would have allowed 
for subgroup analyses by site of hnc.
The most common presenting symptom for hnc in our 
cohort was a neck mass, followed by pain at the primary 
cancer site and a mouth sore. Other studies have found that 
the presence of a neck mass or lymphatic metastasis has 
resulted in a shorter patient delay17,20,23. Pain was the sec-
ond most common presenting symptom in our study. Two 
studies found that pain has no effect on patient delay17,24, 
and one study found a shorter patient delay for patients ex-
periencing pain20. In a mixed-methods study by Lee et al., 
reasons for patient delay reported by patients included a 
lack of awareness of the signs and symptoms of hnc (61% 
TABLE III Cancer characteristics
Characteristic Stage [n (%)]
Early Advanced Overall
Patients 43 51 102a
Histology
Squamous cell carcinoma 34 (79.1) 41 (80.4) 80 (78.4)
Other 9 (20.9) 10 (19.6) 22 (21.6)
Site
Oral cavity 17 (39.5) 12 (23.5) 31 (30.4)
Oropharynx 5 (11.6) 14 (27.5) 20 (19.6)
Salivary glands 7 (16.3) 3 (5.9) 13 (12.7)
Larynx 5 (11.6) 6 (11.8) 11 (10.8)
Hypopharynx 0 (0) 4 (7.8) 4 (3.9)
Nasal cavity or  
paranasal sinuses
1 (2.3) 1 (2.0) 2 (2)
Other 8 (18.6) 9 (17.7) 21 (20.1)
AJCC stage
I 21 (48.8) 0 (0) 21 (20.6)
II 22 (51.2) 0 (0) 22 (21.6)
III 0 (0) 18 (35.3) 18 (17.6)
IV 0 (0) 33 (64.7) 33 (32.4)
Unknown 0 (0) 0 (0) 8 (7.8)
T Stage
T1 20 (46.5) 7 (13.7) 27 (26.5)
T2 21 (48.8) 14 (27.5) 35 (34.3)
T3 2 (4.7) 10 (19.6) 12 (11.8)
T4 0 (0) 20 (39.2) 20 (19.6)
Tx 0 (0) 0 (0) 8 (7.8)
N Stage
N0 37 (86.0) 10 (19.6) 47 (46.1)
N1 3 (7) 12 (23.5) 15 (14.7)
N2 1 (2.3) 24 (47.1) 28 (27.5)
N3 0 (0) 3 (5.9) 3 (2.9)
Nx 2 (4.7) 2 (3.9) 9 (8.8)
M Stage
M0 36 (83.7) 41 (80.4) 77 (75.5)
M1 0 (0) 2 (3.9) 2 (2)
Mx 7 (16.3) 8 (15.7) 23 (22.5)
a Of 102 total patients, 8 had disease of unknown stage based on 
American Joint Committee on Cancer criteria. Of 80 patients with 
squamous cell carcinoma and 22 with “other” histology, 5 and 3 
respectively had disease of unknown stage.
of patients), believing that alternative medicines would 
cure their disease (20% of patients), and not knowing that 
smoking and alcohol could cause hnc (57% of patients)13. 
Lack of awareness, education, and knowledge of the risk 
factors for hnc—plus the low profile of hnc in the public 
media—might all be factors contributing to patient delay 
and thus deserving of further study3,20.
We did not find that sociodemographic or socioeco-
nomic factors correlated with mean patient delay; however, 
when patients were asked about their perception of delay, 
patients who lived alone were more likely to delay seeking 
medical attention. The finding of no correlation between 
sociodemographic or socioeconomic factors and patient 
delay is consistent with results in other studies17,21,23,24.
Smoking status and alcohol consumption also did not 
appear to affect patient delay. Previous studies in Finland, 
which has a national public health care system and allows 
patients to seek medical care regardless of income, have 
demonstrated that a lower socioeconomic status leads to 
longer patient delays26,27.
Our study highlighted regret on the part of more than 
half the patients that they did not seek attention sooner. 
Addressing patient delay is more complex than simply 
providing education about the risk factors for hnc, or 
awareness or screening campaigns. A review by Noonan26 
about patient delay in oral cancer suggests that application 
of a psychosocial theoretical model to studies in the field 
of diagnostic delay should be used, because the perception 
of the signs of cancer by patients might be misunderstood 
and lead patients to erroneous behavioural responses that 
might delay them in seeking medical attention26.
The longest period of delay was found in the provider 
interval: almost 11 months from the first hcp visit to the 
first mdt clinic visit. It is worth noting that this particular 
delay interval is variably defined in the literature. Some 
publications describe physician delay as the interval from 
first hcp visit to date of diagnosis (biopsy date)19; others 
describe diagnostic delay as the time from referral by a 
hcp to the final treatment decision by a multidisciplinary 
tumour conference22. We chose to define provider delay as 
the time from first hcp presentation to presentation at the 
mdt clinic so as to ensure that the entire time from first 
contact with a hcp until the treatment decision was made 
in the mdt clinic was included.
In Ontario, regionalization of hnc care has resulted 
in all patients with hnc being treated at a small number of 
high-volume hnc centres. In the past, patients might have 
been treated by community head-and-neck surgeons or 
radiation oncologists working in smaller centres, but to-
day’s patients might first have to be seen by a community 
otolaryngologist or oral surgeon for diagnosis. They are 
then referred to the regional hnc treatment centre. We 
hypothesized that the new pathway might result in longer 
provider delays and multiple hcp referrals. We found that 
the provider delay was substantially longer than the delay 
that has been reported in the literature. The mean provider 
delay in our study was 11 months. A previous study conduct-
ed in Ontario in 2016 demonstrated a mean provider delay 
of 8.3 months—although the patients in that study were 
seen by a head-and-neck surgeon and not at a mdt clinic13. 
Other studies have demonstrated shorter provider delays 
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outside of the Canadian health care system: approximately 
3–5 months in the United Kingdom and 3 months in the 
United States3,6,7.
Although we did not examine whether provider delays 
have become longer since the regionalization of hnc care, 
regionalization might have contributed to a longer delay in 
our study than in others. We also found that patients saw 
a mean of 3 hcps (range: 1–7) before being seen at the mdt 
clinic. Although the provider delay in our study did not 
affect stage at presentation, a mean delay of 11 months, 
with several referrals to hcps, is undoubtedly prolonged and 
unacceptable. That length of delay could lead to increased 
patient anxiety and lack of trust in the health care system, 
with more than half the patients in our study experiencing 
regret and stating that they wished they had done things 
differently. Although treatment at high-volume head-and-
neck cancer centres has been shown to lead to improved 
outcomes for patients28,29, the effect that regionalization 
has had on diagnostic delay and patient care has not been 
thoroughly studied. We demonstrated that significant im-
provement could be made in provider delay in that regard.
Several components of the interval between first pres-
entation to a hcp and the mdt clinic visit could have contrib-
uted to provider delay. Lack of a family doctor or poor access 
to a family doctor might have contributed, given that 30% 
of the patients in the present study presented to a hcp other 
than their family doctor. Provider education about the signs 
and symptoms of hnc might have contributed to provider 
delay, given that almost 40% of patients presented with a 
neck mass, which might have been interpreted by hcps as 
having an infectious cause. Further, only 22% of patients 
were current smokers, which is a common risk factor for 
hnc and might have resulted in a lower suspicion of hnc 
by the hcp. The diagnostic workup and referral process 
might also have contributed to provider delay, including 
wait times for imaging, biopsy, and specialist referrals. 
A previous Canadian study identified lack of physician 
knowledge as a theme related to provider delay, identi-
fying 3 subthemes, including inappropriate prescription 
of medications for infection or gastroesophageal reflux 
TABLE IV Intervals for diagnostic pathway events from symptom onset to first multidisciplinary team (MDT) visit
Event Mean interval (months), by stage
From To Early Advanced Overall
First symptom onset 1st HCP visita 5.51±16.09 2.03±3.83 3.93±11.71 0.18
Appointment made 1st HCP visit 0.17±0.35 0.31±0.61 0.23±0.50 0.18
First HCP visit Imaging (US, CT, and MRI) 9.39±20.60 6.43±11.77 8.12±16.19 0.41
First HCP visit Biopsy 10.73±22.99 8.21±13.79 9.83±18.27 0.60
First symptom onset MDT visit 16.23±27.73 10.27±14.19 15.07±31.54 0.21
First HCP visit MDT visit 10.95±20.04 8.04±12.59 10.74±20.00 0.39
HCPs seen Patients [n (%)] p Value
 <3 17 (40.5) 25 (49.0) 45 (44.1) 0.41
 ≥3 25 (59.5) 26 (51.0) 56 (54.9) 0.41
a Most common first HCP seen was a family doctor (69.6% of total). Most common second, third, fourth, and fifth HCP seen was an otolaryngol-
ogist outside of the MDT clinic.
HCP = health care practitioner; US = ultrasonography; CT = computed tomography; MRI = magnetic resonance imaging.
disease, lack of knowledge about the signs and symptoms 
of hnc, and inappropriate reassurance of good heath by 
hcps13. Provider delay was longer than patient delay in 
our study, suggesting that the more effective intervention 
might be to focus first on shortening the total diagnostic 
delay. Possible ways to shorten provider delay include 
improving training for physicians and dentists about the 
signs and symptoms of hnc, providing continuing medical 
education about hnc, targeting dentists (who represented a 
significant proportion of the hcps in our study), and stream-
lining the referral process so that patients avoid multiple 
referrals. Studies assessing educational programs or tools 
for physicians-in-training would be very useful.
The strengths of our study lie in the complete charac-
terization of each patient’s pathway to the mdt clinic. Previ-
ous studies have defined provider delay as the interval from 
first contact with a hcp to the date of diagnosis. However, in 
the health care system today, treatment decisions are not 
made until the patient is seen at the mdt clinic, and patients 
could experience further delay while waiting for imaging 
and referral to the mdt clinic. Other strengths include 
our description of the numbers and types of hcps seen, 
the timing of patient appointments, and the perception 
of patients about their diagnostic care pathway. Further-
more, all those factors are viewed from the perspective of 
the Canadian health care system, eliminating some of the 
socioeconomic barriers that are a factor in other countries. 
Studies conducted in health care systems outside of Can-
ada do not detail as many intervals in appointments and 
do not specify which hcps were seen19,30,31. Furthermore, 
our study is prospective; other studies that have looked 
at similar data have been significantly affected by recall 
bias because of their retrospective design. Although re-
call bias remains an issue in the present study because 
of patient reporting, the prospective design reduces the 
effect. We tried to minimize recall bias by having patients 
complete the questionnaire during their first encounter at 
the mdt clinic. We also included all hnc sites and analyzed 
delay as a continuous variable. Certain studies have fo-
cused on the oral cavity alone and have therefore focused 
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on the diagnostic sensitivity of hcps with respect to lesions 
of the oral cavity4,31,32. However, many other symptoms, 
such as neck lumps, can be just as easily misdiagnosed 
or overlooked. Finally, we developed a survey based on a 
previously validated survey. We assisted patients in com-
pleting the survey, and we recruited consecutive patients.
Our study is limited in a number of ways. The first 
limitation is recall bias. Patients were asked to recall their 
awareness of their symptoms and their contact with hcps, 
both of which can be influenced by inaccurate recall. We 
attempted to mitigate that limitation with a prospective de-
sign and a survey that was created to be as clear as possible, 
with precise instructions. However, we were not able to 
determine how accurate were the patient’s responses about 
the delay experienced. The questionnaire was adminis-
tered after the cancer diagnosis, during a stressful med-
ical appointment in which patients were being informed 
of their treatment options. That environment might have 
affected the ability to accurately recall onset of symptoms, 
potentially leading to a falsely reconstructed sequence of 
events, given that the outcome was known to the patient. 
Further, the recall bias could have varied depending on the 
patient’s symptoms, because some symptoms might have 
been more prominent than others. Patients-reported data 
concerning the duration of their symptoms are subject-
ive and might have been underestimated, given that the 
patients were aware of the cancer diagnosis.
A second issue is the small sample size, which might 
have resulted in associations not being observed. In addi-
tion, only 22% of our sample were current smokers; the 
proportion of smokers in similar studies tends to be sig-
nificantly higher, indicating that our sample might not be 
completely representative22,23.
Yet another limitation, particularly relevant to the 
Canadian health care system and cancer care in Ontario, 
is that we did not consider distance traveled and econom-
ic limitations. The number of designated hnc sites within 
the regional model in Ontario is small, which can lead to 
patients having to travel long distances for care.
CONCLUSIONS
We observed a significant duration of diagnostic delay, 
with the greatest delay being experienced as provider 
delay. Whether the observed lengthened intervals in the 
diagnostic timeline affect patient outcomes is still unclear. 
Certain measures could be taken to shorten the diagnos-
tic delay, including educating hcps and streamlining the 
referral process in the era of regionalization of hnc care. 
Future research should explore the efficacy of such inter-
ventions, and ultimately, whether those interventions 
result in improved outcomes.
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